All patients
Age < 65y (younger) Age > 65y ECOG 0 ECOG 1 Gender, female Gender, male Hemoglobin concentration < 10g/dl hemoglobin concentration > 10g/dl metastasis (liver ) metastasis (lymph node ) metastasis (visceral) smoker (Current) smoker (Former) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
urothelial cancer (UC) - bladder cancer (BC), durvalumab alone vs. platinum derivate, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results DANUBE (D vs C - all population), 2020 0.99 [0.83; 1.18]
DANUBE (D vs C - PDL1>25%), 2020 0.89 [0.71; 1.11]
0.95 [0.83 ; 1.09 ] DANUBE (D vs C - all population), 2020, DANUBE (D vs C - PDL1>25%), 2020 2 0% 1,106 moderate not evaluable progression or deaths (PFS)detailed results DANUBE (D vs C - all population), 2020 0.77 [0.54; 1.09]
DANUBE (D vs C - PDL1>25%), 2020 1.24 [0.74; 2.08]
0.94 [0.59 ; 1.50 ] DANUBE (D vs C - all population), 2020, DANUBE (D vs C - PDL1>25%), 2020 2 56% 1,106 moderate not evaluable DORdetailed results DANUBE (D vs C - all population), 2020 0.35 [0.20; 0.62]
DANUBE (D vs C - PDL1>25%), 2020 0.27 [0.13; 0.57]
0.32 [0.20 ; 0.50 ] DANUBE (D vs C - all population), 2020, DANUBE (D vs C - PDL1>25%), 2020 2 0% 416 moderate not evaluable objective responses (ORR)detailed results DANUBE (D vs C - all population), 2020 0.36 [0.26; 0.49]
DANUBE (D vs C - PDL1>25%), 2020 0.41 [0.27; 0.62]
0.38 [0.29 ; 0.49 ] DANUBE (D vs C - all population), 2020, DANUBE (D vs C - PDL1>25%), 2020 2 0% 1,106 moderate not evaluable AE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.37 [0.27; 0.52]
0.37 [0.27 ; 0.52 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results DANUBE (D vs C - all population), 2020 0.66 [0.43; 1.03]
0.66 [0.43 ; 1.03 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable SAE (any grade)detailed results DANUBE (D vs C - all population), 2020 1.01 [0.74; 1.39]
1.01 [0.74 ; 1.39 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable STRAE (any grade)detailed results DANUBE (D vs C - all population), 2020 0.50 [0.31; 0.81]
0.50 [0.31 ; 0.81 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable TRAE (any grade)detailed results DANUBE (D vs C - all population), 2020 0.13 [0.09; 0.21]
0.13 [0.09 ; 0.21 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.10 [0.07; 0.15]
0.10 [0.07 ; 0.15 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable TRAE leading to death (grade 5)detailed results DANUBE (D vs C - all population), 2020 1.82 [0.16; 20.16]
1.82 [0.16 ; 20.16 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable TRAE leading to discontinuation (any grade)detailed results DANUBE (D vs C - all population), 2020 0.46 [0.26; 0.79]
0.46 [0.26 ; 0.79 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Abdominal pain TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 3.64 [0.16; 81.12]
3.64 [0.16 ; 81.12 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Acute kidney injury TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.45 [0.02; 13.55]
0.45 [0.02 ; 13.55 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
0.91 [0.02 ; 45.86 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Alopecia TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 1.82 [0.06; 54.35]
1.82 [0.06 ; 54.35 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Anaemia TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.05 [0.02; 0.13]
0.05 [0.02 ; 0.13 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Arthralgia TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
0.91 [0.02 ; 45.86 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Arthritis TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
0.91 [0.02 ; 45.86 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Asthenia TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.25 [0.05; 1.24]
0.25 [0.05 ; 1.24 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Blood creatinine increased TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.45 [0.02; 13.55]
0.45 [0.02 ; 13.55 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Colitis TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
0.91 [0.02 ; 45.86 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Constipation TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
0.91 [0.02 ; 45.86 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.68 [0.15; 3.05]
0.68 [0.15 ; 3.05 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Diabetes TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
0.91 [0.02 ; 45.86 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.36 [0.07; 1.86]
0.36 [0.07 ; 1.86 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Dyspnoea TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 3.64 [0.16; 81.12]
3.64 [0.16 ; 81.12 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Fatigue TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.11 [0.01; 0.89]
0.11 [0.01 ; 0.89 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.15 [0.01; 3.01]
0.15 [0.01 ; 3.01 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Gastritis TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
0.91 [0.02 ; 45.86 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Guillain-Barré syndrome TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 1.82 [0.06; 54.35]
1.82 [0.06 ; 54.35 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 5.48 [0.27; 109.88]
5.48 [0.27 ; 109.88 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Hypersensitivity TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.45 [0.02; 13.55]
0.45 [0.02 ; 13.55 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
0.91 [0.02 ; 45.86 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Hypophysitis TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
0.91 [0.02 ; 45.86 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
0.91 [0.02 ; 45.86 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Increase AST TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.13; 6.48]
0.91 [0.13 ; 6.48 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 2.74 [0.28; 26.45]
2.74 [0.28 ; 26.45 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Increased lipase level TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 6.46 [0.79; 52.82]
6.46 [0.79 ; 52.82 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
0.91 [0.02 ; 45.86 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Leucopenia TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.04 [0.00; 0.62]
0.04 [0.00 ; 0.62 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Myocarditis TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 3.64 [0.16; 81.12]
3.64 [0.16 ; 81.12 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Myositis TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 1.82 [0.06; 54.35]
1.82 [0.06 ; 54.35 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Nausea TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.06 [0.00; 0.97]
0.06 [0.00 ; 0.97 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Nephritis TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 3.64 [0.16; 81.12]
3.64 [0.16 ; 81.12 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results Out of scale DANUBE (D vs C - all population), 2020 0.01 [0.00; 0.09]
0.01 [0.00 ; 0.09 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Pancreatitis TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
0.91 [0.02 ; 45.86 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Pancytopenia TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.11 [0.01; 2.13]
0.11 [0.01 ; 2.13 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 3.64 [0.16; 81.12]
3.64 [0.16 ; 81.12 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Pruritic rash TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
0.91 [0.02 ; 45.86 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Pruritus TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 1.82 [0.06; 54.35]
1.82 [0.06 ; 54.35 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Pyrexia TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.23 [0.01; 5.02]
0.23 [0.01 ; 5.02 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Rash TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 3.64 [0.16; 81.12]
3.64 [0.16 ; 81.12 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Sepsis TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.06; 14.56]
0.91 [0.06 ; 14.56 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Stevens-Johnson syndrome TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 1.82 [0.06; 54.35]
1.82 [0.06 ; 54.35 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Stomatitis TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
0.91 [0.02 ; 45.86 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.02 [0.00; 0.29]
0.02 [0.00 ; 0.29 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Thyroiditis TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
0.91 [0.02 ; 45.86 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable Vomiting TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.09 [0.00; 1.64]
0.09 [0.00 ; 1.64 ] DANUBE (D vs C - all population), 2020 1 0% 658 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-03 14:12 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 11,288,153,157,290,155,154,289,188,189,239,158,252,253,76,238,236,237
- treatments: 374